AK112-101
03 Nov 2020
AK112-101
NCT04047290
A Phase 1a/1b, Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK112 in Subjects With Advanced Solid Tumors
AkesoBio
Cancer Type | All cancers |
---|---|
Trial Type | Treatment |
Phase | Phase I |
Age Range | 18 years and older |
Sex | Both |
Tumour Stream | - |
Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
Anticipated Start Date | 2019-08-15 |
Anticipated End Date | 2022-12-30 |
Hospital | Ashford Cancer Centre Research |
---|---|
Clinical Trial Coordinator | Sue Yeend |
syeend@adelaidecancercentre.com.au | |
Phone | 08 8292 2240 |
Principal Investigator | Dr Anna Mislang |
Recruitment Status | Recruiting |